Methotrexate and misoprostol when surgical abortion fails

被引:16
作者
Schaff, EA [1 ]
Wortman, M [1 ]
Eisinger, SH [1 ]
Franks, P [1 ]
机构
[1] UNIV ROCHESTER,DEPT OBSTET & GYNECOL,ROCHESTER,NY 14620
关键词
D O I
10.1016/0029-7844(95)00406-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To describe the use of methotrexate and misoprostol to induce abortion in pregnancies up to 8 weeks when uterine or cervical anomalies make suction curettage difficult or impossible. Methods: Four consecutive women, 8 weeks pregnant or less and with failed suction curettage, were given methotrexate 50 mg per square meter intramuscularly followed by a misoprostol 800-mu g vaginal suppository 72 hours later. A repeat dose of a misoprostol 800-mu g suppository was administered on day 4 if there was no bleeding, and an additional dose was given if the repeat beta-hCG titer had not decreased by at least 50%. Subjects were followed-up with serum or urine hCG assays. Complete abortion was defined by vaginal bleeding and a negative urine pregnancy test. Subjects completed a daily symptom log and a satisfaction questionnaire when the abortion was complete. Results: The four women referred after failed suction curettage had the following anatomic problems: a uterus bicornis bicollis, a bicornuate uterus, uterine leiomyomas, and cervical stenosis resulting from previous laser surgery. All subjects had a complete abortion from methotrexate and misoprostol. Mild gastrointestinal side effects were reported by all four subjects: nausea (two subjects), vomiting (two), and diarrhea (two). The satisfaction questionnaire revealed that all subjects agreed with the statements that ''Overall, the procedure went well'' and ''I would recommend this procedure over a surgical abortion.'' Conclusion: Methotrexate and misoprostol can induce an abortion when uterine or cervical anomalies make suction curettage difficult or impossible.
引用
收藏
页码:450 / 452
页数:3
相关论文
共 12 条
[1]   THE RISK OF SERIOUS COMPLICATIONS FROM INDUCED-ABORTION - DO PERSONAL CHARACTERISTICS MAKE A DIFFERENCE [J].
BUEHLER, JW ;
SCHULZ, KF ;
GRIMES, DA ;
HOGUE, CJR .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 153 (01) :14-20
[2]   METHOTREXATE AND MISOPROSTOL FOR EARLY ABORTION [J].
CREININ, MD ;
DARNEY, PD .
CONTRACEPTION, 1993, 48 (04) :339-348
[3]   METHOTREXATE AND MISOPROSTOL VS MISOPROSTOL ALONE FOR EARLY ABORTION - A RANDOMIZED CONTROLLED TRIAL [J].
CREININ, MD ;
VITTINGHOFF, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (15) :1190-1195
[4]   METHOTREXATE FOR ABORTION AT LESS-THAN-OR-EQUAL-TO-42 DAYS GESTATION [J].
CREININ, MD .
CONTRACEPTION, 1993, 48 (06) :519-525
[5]   INTRAVAGINAL MISOPROSTOL AS A CERVICAL RIPENING AGENT [J].
FLETCHER, HM ;
MITCHELL, S ;
SIMEON, D ;
FREDERICK, J ;
BROWN, D .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (07) :641-644
[6]   METHOTREXATE AND MISOPROSTOL TO TERMINATE EARLY-PREGNANCY [J].
HAUSKNECHT, RU .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :537-540
[7]  
LINDBLOM B, 1992, CURR OPIN OBSTET GYN, V4, P400
[8]   SEQUENTIAL USE OF METHOTREXATE AND ACTINOMYCIN D IN TREATMENT OF METASTATIC CHORIOCARCINOMA AND RELATED TROPHOBLASTIC DISEASES IN WOMEN [J].
ROSS, GT ;
GOLDSTEIN, DP ;
HERTZ, R ;
LIPSETT, MB ;
ODELL, WD .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1965, 93 (02) :223-+
[9]  
SANCHEZRAMOS L, 1993, OBSTET GYNECOL, V81, P332
[10]  
Schaff E A, 1995, Arch Fam Med, V4, P774, DOI 10.1001/archfami.4.9.774